MAO A/HSP90-IN-2

MAO A/HSP90-IN-2

• CAS Number: 2927489-99-2
• UNSPSC Description: MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape[1].
• Target Antigen: HSP; Monoamine Oxidase
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Neuronal Signaling
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/mao-a-hsp90-in-2.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=C(C=C(C(C(C)C)=C1)O)O)N(C2=CC(Cl)=C(C=C2)OCCCN(CC#C)C)CC
• Molecular Weight: 458.98
• References & Citations: [1]1、Hui-Ju Tseng, et al. Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma. European Journal of Medicinal Chemistry. Volume 256, 5 August 2023, 115459.|[2]Hui-Ju Tseng, et al. Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma. European Journal of Medicinal Chemistry. Volume 256, 5 August 2023, 115459.
• Shipping Conditions: Room temperature
• Clinical Information: Phase 1